Literature DB >> 28368375

Multiple myeloma patients in long-term complete response after autologous stem cell transplantation express a particular immune signature with potential prognostic implication.

A Arteche-López1, A Kreutzman2, A Alegre3, P Sanz Martín1, B Aguado3, M González-Pardo3, M Espiño4, L M Villar4, D García Belmonte5, R de la Cámara5, C Muñoz-Calleja2.   

Abstract

The proportion of multiple myeloma patients in long-term complete response (LTCR-MM) for more than 6 years after autologous stem cell transplantation (ASCT) is small. To evaluate whether this LTCR is associated with a particular immune signature, peripheral blood samples from 13 LTCR-MM after ASCT and healthy blood donors (HBD) were analysed. Subpopulations of T-cells (naïve, effector, central memory and regulatory), B-cells (naïve, marginal zone-like, class-switched memory, transitional and plasmablasts) and NK-cells expressing inhibitory and activating receptors were quantified by multiparametric flow cytometry (MFC). Heavy/light chains (HLC) were quantified by nephelometry. The percentage of CD4+ T-cells was lower in patients, whereas an increment in the percentage of CD4+ and CD8+ effector memory T-cells was associated with the LTCR. Regulatory T-cells and NK-cells were similar in both groups but a particular redistribution of inhibitory and activating receptors in NK-cells were found in patients. Regarding B-cells, an increase in naïve cells and a corresponding reduction in marginal zone-like and class-switched memory B-cells was observed. The HLC values were normal. Our results suggest that LTCR-MM patients express a particular immune signature, which probably reflects a 'high quality' immune reconstitution that could exert a competent anti-tumor immunological surveillance along with a recovery of the humoral immunity.

Entities:  

Mesh:

Year:  2017        PMID: 28368375     DOI: 10.1038/bmt.2017.29

Source DB:  PubMed          Journal:  Bone Marrow Transplant        ISSN: 0268-3369            Impact factor:   5.483


  47 in total

Review 1.  Surface NK receptors and their ligands on tumor cells.

Authors:  Lorenzo Moretta; Cristina Bottino; Daniela Pende; Roberta Castriconi; Maria Cristina Mingari; Alessandro Moretta
Journal:  Semin Immunol       Date:  2006-05-26       Impact factor: 11.130

2.  The immunophenotypic attributes of NK cells and NK-cell lineage lymphoproliferative disorders.

Authors:  William G Morice
Journal:  Am J Clin Pathol       Date:  2007-06       Impact factor: 2.493

3.  Long-term prognostic significance of response in multiple myeloma after stem cell transplantation.

Authors:  Joaquin Martinez-Lopez; Joan Blade; María-Victoria Mateos; Carlos Grande; Adrián Alegre; José García-Laraña; Anna Sureda; Javier de la Rubia; Eulogio Conde; Rafael Martinez; Felipe de Arriba; Maria C Viguria; Joan Besalduch; Rafael Cabrera; José D Gonzalez-San Miguel; José Luis Guzman-Zamudio; Maria Carmen Gomez del Castillo; José Maria Moraleda; Juan C García-Ruiz; Jesús San Miguel; Juan José Lahuerta
Journal:  Blood       Date:  2011-04-11       Impact factor: 22.113

4.  The natural killer-activating receptor, NKG2D, on CD3+CD8+ T cells plays a critical role in identifying and killing autologous myeloma cells.

Authors:  Laleh Talebian; Dawn A Fischer; Jillian Wu; Jacqueline Y Channon; Charles L Sentman; Marc S Ernstoff; Kenneth R Meehan
Journal:  Transfusion       Date:  2014-01-22       Impact factor: 3.157

5.  T-cell Exhaustion in Multiple Myeloma Relapse after Autotransplant: Optimal Timing of Immunotherapy.

Authors:  David J Chung; Katherine B Pronschinske; Justin A Shyer; Sneh Sharma; Samantha Leung; Shane A Curran; Alexander M Lesokhin; Sean M Devlin; Sergio A Giralt; James W Young
Journal:  Cancer Immunol Res       Date:  2015-10-13       Impact factor: 11.151

6.  Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab.

Authors:  Michael S van der Veer; Michel de Weers; Berris van Kessel; Joost M Bakker; Shulamiet Wittebol; Paul W H I Parren; Henk M Lokhorst; Tuna Mutis
Journal:  Haematologica       Date:  2010-11-25       Impact factor: 9.941

7.  Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

Authors:  J A Katzmann; R Clark; R A Kyle; D R Larson; T M Therneau; L J Melton; J T Benson; C L Colby; A Dispenzieri; O Landgren; S Kumar; A R Bradwell; J R Cerhan; S V Rajkumar
Journal:  Leukemia       Date:  2012-07-11       Impact factor: 11.528

Review 8.  Targeting the PD-1/PD-L1 axis in multiple myeloma: a dream or a reality?

Authors:  Jacalyn Rosenblatt; David Avigan
Journal:  Blood       Date:  2016-12-05       Impact factor: 22.113

9.  New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells.

Authors:  Ernesto Pérez-Persona; María-Belén Vidriales; Gema Mateo; Ramón García-Sanz; Maria-Victoria Mateos; Alfonso García de Coca; Josefina Galende; Guillermo Martín-Nuñez; José M Alonso; Natalia de Las Heras; José M Hernández; Alejandro Martín; Consuelo López-Berges; Alberto Orfao; Jesús F San Miguel
Journal:  Blood       Date:  2007-06-18       Impact factor: 22.113

10.  CR represents an early index of potential long survival in multiple myeloma.

Authors:  M Wang; K Delasalle; L Feng; S Thomas; S Giralt; M Qazilbash; B Handy; J J Lee; R Alexanian
Journal:  Bone Marrow Transplant       Date:  2009-07-27       Impact factor: 5.483

View more
  8 in total

1.  The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma.

Authors:  Antonio Curti; Roberto M Lemoli; Giulia Tolomelli; Katia Mancuso; Paola Tacchetti; Francesca Patriarca; Monica Galli; Lucia Pantani; Beatrice Zannetti; Maria Rosa Motta; Simonetta Rizzi; Elisa Dan; Barbara Sinigaglia; Valeria Giudice; Andrea Olmo; Mario Arpinati; Gabriella Chirumbolo; Renato Fanin; Russell E Lewis; Laura Paris; Francesca Bonifazi; Michele Cavo
Journal:  Bone Marrow Transplant       Date:  2019-11-25       Impact factor: 5.483

2.  Immunophenotypic Characteristics of Bone Marrow Microenvironment Cellular Composition at the Biochemical Progression of Multiple Myeloma.

Authors:  Agnieszka Krzywdzińska; Bartosz Puła; Donata Szymczak; Aneta Milanowska; Agnieszka Szeremet; Krzysztof Jamroziak
Journal:  J Clin Med       Date:  2022-06-27       Impact factor: 4.964

3.  The metabolic profile of reconstituting T-cells, NK-cells, and monocytes following autologous stem cell transplantation and its impact on outcome.

Authors:  Benedikt Jacobs; Dimitrios Mougiakakos; Silja Richter; Martin Böttcher; Simon Völkl; Andreas Mackensen; Evelyn Ullrich
Journal:  Sci Rep       Date:  2022-07-06       Impact factor: 4.996

4.  Characterization and prognostic implication of delayed complete response in AL amyloidosis.

Authors:  Eli Muchtar; Morie A Gertz; Shaji K Kumar; Martha Q Lacy; Nelson Leung; Francis K Buadi; David Dingli; Suzanne R Hayman; Ronald S Go; Prashant Kapoor; Wilson Gonsalves; Taxiarchis V Kourelis; Rahma Warsame; Yi Lisa Hwa; Amie Fonder; Miriam Hobbs; Stephen Russell; John A Lust; Mustaqueem Siddiqui; S Vincent Rajkumar; Robert A Kyle; Angela Dispenzieri
Journal:  Eur J Haematol       Date:  2020-12-04       Impact factor: 2.997

5.  Mass cytometry dissects T cell heterogeneity in the immune tumor microenvironment of common dysproteinemias at diagnosis and after first line therapies.

Authors:  Taxiarchis V Kourelis; Jose C Villasboas; Erik Jessen; Surendra Dasari; Angela Dispenzieri; Dragan Jevremovic; Shaji Kumar
Journal:  Blood Cancer J       Date:  2019-08-28       Impact factor: 11.037

6.  Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma.

Authors:  Ashley Paquin; Alissa Visram; Shaji K Kumar; Morie A Gertz; Hafsa Cantwell; Francis K Buadi; Martha Q Lacy; Angela Dispenzieri; David Dingli; Lisa Hwa; Amie Fonder; Miriam Hobbs; Suzanne R Hayman; John A Lust; Stephen J Russell; Nelson Leung; Prashant Kapoor; Ronald S Go; Yi Lin; Wilson I Gonsalves; Taxiarchis Kourelis; Rahma Warsame; Robert A Kyle; S Vincent Rajkumar
Journal:  Blood Cancer J       Date:  2020-08-28       Impact factor: 11.037

7.  Polyclonal Immunoglobulin Recovery after Autologous Stem Cell Transplantation Is an Independent Prognostic Factor for Survival Outcome in Patients with Multiple Myeloma.

Authors:  Shuji Ozaki; Takeshi Harada; Hikaru Yagi; Etsuko Sekimoto; Hironobu Shibata; Toshio Shigekiyo; Shiro Fujii; Shingen Nakamura; Hirokazu Miki; Kumiko Kagawa; Masahiro Abe
Journal:  Cancers (Basel)       Date:  2019-12-18       Impact factor: 6.639

Review 8.  Human NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment.

Authors:  Ane Orrantia; Iñigo Terrén; Gabirel Astarloa-Pando; Olatz Zenarruzabeitia; Francisco Borrego
Journal:  Cancers (Basel)       Date:  2021-03-30       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.